Schizoaffective Disorders Terminated Phase 3 Trials for Ziprasidone (DB00246)

Also known as: Schizoaffective disorder / Schizophrenia schizoaffective / Schizoaffective psychosis / Schizo-affective type schizophrenia

IndicationStatusPhase
DBCOND0033299 (Schizoaffective Disorders)Terminated3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00288353Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic ChangesTreatment
NCT00645229A Study of the Efficacy and Safety of Ziprasidone in Patients With Acute Exacerbation of Schizophrenia or Schizoaffective DisorderTreatment